N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nykode Therapeutics ASA
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Selling, General & Administrative
-$30.3m
CAGR 3-Years
-16%
CAGR 5-Years
-80%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Selling, General & Administrative
-kr66.3m
CAGR 3-Years
-15%
CAGR 5-Years
-18%
CAGR 10-Years
-12%
B
Bergenbio ASA
OSE:BGBIO
Selling, General & Administrative
-kr54m
CAGR 3-Years
18%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Selling, General & Administrative
-kr24.3m
CAGR 3-Years
-1%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Selling, General & Administrative
-kr62.5m
CAGR 3-Years
-14%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
T
Thor Medical ASA
OSE:TRMED
Selling, General & Administrative
-kr7.8m
CAGR 3-Years
54%
CAGR 5-Years
38%
CAGR 10-Years
1%
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
918.2m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.181 NOK
Overvaluation 94%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Selling, General & Administrative?
Selling, General & Administrative
-30.3m USD

Based on the financial report for Jun 30, 2024, Nykode Therapeutics ASA's Selling, General & Administrative amounts to -30.3m USD.

What is Nykode Therapeutics ASA's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-80%

Over the last year, the Selling, General & Administrative growth was -20%. The average annual Selling, General & Administrative growth rates for Nykode Therapeutics ASA have been -16% over the past three years , -80% over the past five years .

Back to Top